Shanghai, China, 08 August 2015 —MicroPort® VisionPower announced that its YINI® Cataract Phacoemulsification System (YINI®) received marketing approval from the National Medical Products Administration (NMPA) of China on July 25.
YINI® is a floor-standing Cataract Phacoemulsification System designed for modern cataract surgery, with particular attention to complex cases. It features advanced ultrasound energy control and fluid management technologies, which help maintain stable intraocular pressure and efficient nucleus fragmentation during surgery.
At the heart of the system is a six-piece piezoelectric ceramic transducer, paired with a horn-shaped needle tip for enhanced stability and grip during lens fragmentation. Its fluid management module includes a non-contact pressure sensor for continuous intraocular pressure monitoring, as well as a high-performance peristaltic pump with a rigid fluid path and tapered rollers to minimized occlusion surges. A flexible silicone membrane provides reliable negative pressure exceeding 650 mmHg for consistent aspiration.
YINI® represents MicroPort® VisionPower’s efforts to develop integrated core platforms in ultrasound, fluid dynamics, materials, and optics. These capabilities not only support the YINI® system but also lay the foundation for future innovations in ophthalmic care.
Dr. Jie Zhang, Chief Technology Officer of MicroPort® Greater China and Chairman of MicroPort® VisionPower, commented: “With cataract surgery being one of the most common procedures globally, we believe the YINI® system will offer a reliable, high-performance option for eye care professional. We are committed to advancing technologies that expand access to quality ophthalmic treatment.”
About MicroPort®
Founded in 1998 on the belief that every person has the right to high quality medical treatments, MicroPort® (MicroPort Scientific Corporation; HKEX: 00853) is a global medical devices company. MicroPort® provides solutions across twelve therapeutic areas, including cardiovascular, orthopedics, cardiac rhythm management, electrophysiology, endovascular, neurovascular and surgical robotics among others. For over 27 years, MicroPort® has been breaking barriers and accelerating access to life-changing solutions so that patients everywhere can continue living better and longer lives. With therapeutic solutions that are available in more than 100 countries and over 20,000 hospitals around the world, today, every 5 seconds or less, a patient around the world benefits from a MicroPort® life-changing solution.
More information is available at: www.microport.com